In support of this, the presence of both VISTA and CD8+ markers is linked to a favorable TME and improved OS, as seen in HCC (75), esophageal adenocarcinoma (79), ovarian cancer (61), and TNBC (64). Here, CD8A is linked to ovarian cancer.